{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,10,19]],"date-time":"2023-10-19T01:26:25Z","timestamp":1697678785160},"reference-count":3,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2006,9,23]],"date-time":"2006-09-23T00:00:00Z","timestamp":1158969600000},"content-version":"vor","delay-in-days":4283,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Archiv der Pharmazie"],"published-print":{"date-parts":[[1995,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The combined effects of the NO\u2010donor RE 2047 with ASA, pentoxifylline, ticlopidine or BM 14515 were determined <jats:italic>in vitro<\/jats:italic> (<jats:italic>Born<\/jats:italic>\u2010test) and <jats:italic>in vivo<\/jats:italic> (rat thrombosis model). The inhibitory effects on platelet aggregation as well as the inhibition of thrombus formation <jats:italic>in vivo<\/jats:italic> were over additive and over independent. The combination of 10 mg\/kg RE 2047 with the same dose of ASA in arterioles (A) showed 70% inhibition of thrombosis (venoles (V): 40%). The respective values for 10 mg\/kg RE 2047 and 10 mg\/kg pentoxifylline are 70% (A) and 35% (V). It is concluded that NO\u2010donors in principle are compounds suitable for the combination with anti\u2010thrombotic drugs of different mechanism of action.<\/jats:p>","DOI":"10.1002\/ardp.19953280113","type":"journal-article","created":{"date-parts":[[2006,10,17]],"date-time":"2006-10-17T08:41:54Z","timestamp":1161074514000},"page":"71-75","source":"Crossref","is-referenced-by-count":9,"title":["New NO\u2010Donors with Antithrombotic and Vasodilating Activities, X: Antiplatelet and Antithrombotic Effects of 3\u2010Methylsydnone\u20105\u2010nitrosimine (RE 2047) in Combination with ASA, Pentoxifylline, and Ticlopidine"],"prefix":"10.1002","volume":"328","author":[{"given":"Kaus","family":"Rehse","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Ciborski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2006,9,23]]},"reference":[{"key":"e_1_2_1_2_2","unstructured":"K.Rehse T.Ciborski Arch. Pharm. (Weinheim) submitted for publication (oligoamine: 26. Mitt.)."},{"key":"e_1_2_1_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/0160-5402(80)90036-4"},{"key":"e_1_2_1_4_2","first-page":"737","volume":"6","author":"Ariens E. J.","year":"1956","journal-title":"Arzneim. Forsch."}],"container-title":["Archiv der Pharmazie"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fardp.19953280113","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ardp.19953280113","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,18]],"date-time":"2023-10-18T01:35:31Z","timestamp":1697592931000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ardp.19953280113"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1995,1]]},"references-count":3,"journal-issue":{"issue":"1","published-print":{"date-parts":[[1995,1]]}},"alternative-id":["10.1002\/ardp.19953280113"],"URL":"https:\/\/doi.org\/10.1002\/ardp.19953280113","archive":["Portico"],"relation":{},"ISSN":["0365-6233","1521-4184"],"issn-type":[{"value":"0365-6233","type":"print"},{"value":"1521-4184","type":"electronic"}],"subject":[],"published":{"date-parts":[[1995,1]]}}}